| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | VIRONGY BIOSCIENCES INC | 11225 ASSETT LOOP | MANASSAS | VA | 20109-4040 | PRINCE WILLIAM | USA | R43IP001230 | PA22-176, SBIR, Phase I, Development of a SARS-CoV-2 emerging variant infectivity and immune evasion panel to quantify the efficacy of vaccine booster induced neutralizing antibodies. | 02 | 1 | CDC | 3/27/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | VIRONGY BIOSCIENCES INC | 11225 ASSETT LOOP | MANASSAS | VA | 20109-4040 | PRINCE WILLIAM | USA | R43IP001230 | PA22-176, SBIR, Phase I, Development of a SARS-CoV-2 emerging variant infectivity and immune evasion panel to quantify the efficacy of vaccine booster induced neutralizing antibodies. | 01 | 1 | CDC | 2/12/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $273,181 ) |
| | 2023 | 2023 | VIRONGY BIOSCIENCES INC | 11225 ASSETT LOOP | MANASSAS | VA | 20109-4040 | PRINCE WILLIAM | USA | R43IP001230 | PA22-176, SBIR, Phase I, Development of a SARS-CoV-2 emerging variant infectivity and immune evasion panel to quantify the efficacy of vaccine booster induced neutralizing antibodies. | 00 | 1 | CDC | 8/23/2023 | $273,181 |
|
|
